Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02369016
Title Phase III Copanlisib in Rituximab-refractory iNHL
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bayer
Indications

marginal zone B-cell lymphoma

lymphoplasmacytic lymphoma

follicular lymphoma

chronic lymphocytic leukemia

Therapies

Copanlisib

Age Groups: adult
Covered Countries ITA


No variant requirements are available.